natgillin/translations-raw huggingface dataset:
A product comprising follicle stimulating hormone (FSH) for use in the treatment of infertility according to any preceding paragraph, wherein the product further comprises a salt comprising a pharmaceutically acceptable alkali metal cation selected from the group consisting of Na+- or K+- salts, or a combination thereof. 
Proizvod, koji sadrži rekombinantni folikulostimulirajući hormon (FSH) dobiven iz ljudske stanične linije za uporabu kod liječenja neplodnosti prema bilo kojem prethodnom zahtjevu, naznačen time da proizvod nadalje sadrži sol, koja sadrži farmaceutski prihvatljiv kation alkalijskog metala, koji je izabran iz skupine, koja sadrži Na*-ili K*- soli ili njihovu kombinaciju.
The method according to claim 1, wherein the dosimeter is at least one of a point dosimeter, a linear array of point dosimeters, a two-dimensional array of point dosimeters, a three-dimensional array of point dosimeters, and at least one two-dimensional dosimeter. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time što je dozimetar najmanje jedan od točkastog dozimetra, linearnog niza točkastih dozimetara, dvodimenzionalnog niza točkastih dozimetara, trodimenzionalnog niza točkastih dozimetara, 1 najmanje jedan dvodimenzionalni dozimetar.
The compound of Claim 1, which is characterized by an x-ray powder diffraction pattern (CuKa λ=1.5418Å at a temperature of about 23°C) comprising four or more 2θ values selected from the group consisting of: 18.0± 0.2,18.4± 0.2, 19.2± 0.2, 19.6± 0.2, 21.2± 0.2, 24.5± 0.2, 25.9± 0.2, and 28.0± 0.2. 
(IV). 2. Spoj prema patentnom zahtjevu 1, naznačen time, što je prikazan dijagramom rendgenske difrakcije praha (CuKo X = 1.5418 A na temperaturi od oko 23%C) koji sadrži četiri ili više 20 vrijednosti izabranih iz grupe koju čine: 18.0 3.
The protection scope of the invention is therefore defined by the enclosed claims. A method for the continuous remote monitoring of a position and advance speed of a pig device inside a pipeline suitable for transporting a pressurized fluid, wherein the pipeline includes a plurality of pipe sections joined to each other by welding seams, the method comprising the following: 
HR P20171911 T1 PATENTNI ZAHTJEVI Postupak kontinuiranog daljinskog praćenja položaja i brzine napredovanja prasice (10) unutar cjevovoda (12) pogodnog za transport fluida pod tlakom, gdje se cjevovod (12) sastoji od više cijevnih odjeljaka, spojenih zajedno zavarivanjem, gdje postupak uključuje sljedeće korake:
the subscript r1 is 0, 1, 2, 3, or 4; and the subscript r2 is 0 or 1. 
donji indeks r1 je 0, 1, 2, 3, ili 4; i donji indeks r2 je 0 ili 1.
A pharmaceutical composition according to any one of claims 1-13, wherein such single dose form comprises one or more antidiabetic compounds selected from the group consisting of GSK-3 inhibitors, retinoid X receptor agonists, Beta-3 AR agonists, UCP modulators, antidiabetic thiazolidinediones, non-glitazone type PPAR gamma agonists, dual PPAR gamma/PPAR alpha agonists, antidiabetic vanadium containing compounds and biguanides. 
Farmaceutska kompozicija prema bilo kojem od paleninih zahtjeva 1-13, naznačena time što takav pojedinačni dozni oblik sadrži jedno ili više antidijabetičkih sredstava izabranih iz grupe koju čine inhibitori GSK-3, agonisti receptora za retinoid X, agonisti Beta-3 AR, modulatori UCP, antidijabetički tiazolidindioni, ne-glitazon tip agonisti PPAR gama, dvostruki PPAR gama/PPAR alfa agonisti, antidijabetički spojevi koji sadrže vanadij i biguanidi.
represents a hydrogen atom or a linear (Cl-C3)alkyl group, in the form of a base or of an addition salt with an acid or with a base. 
predstavlja vodikov atom ili nerazgranatu skupinu (Cl-C3)alkil, u obliku baze ili adicijske soli s kiselinom ili s bazom.
Polyethylene blend comprising from 10 wt% to 90 wt% of recycled high density polyethylene and from 90 wt% to 10 wt% of a virgin polyethylene having a multimodal or broad molecular weight distribution, with weight percentages relative to the total weight of the polyethylene blend, wherein said recycled high density polyethylene is comprising at most 10 wt% of polypropylene and at most 5 wt% of black components, relative to the total weight of said recycled high density polyethylene, and wherein said recycled high density polyethylene is comprising at least 50 ppm of limonene (1-methyl-4-(1-methylethenyl)-cyclohexene, CAS-nr. 
Smjesa polietilena koja se sastoji od 10% do 90% težinskog udjela nerecikliranog polistilena visoke gustoće 1 od 90% do 10% težinskog udjela nerecikliranog polietilena s multimodalnom ili širokom molekularnom raspodjelom težine, s težinskim postocima u odnosu na ukupnu težinu polietilne smjese, naznačeno time da se spomenuti reciklirani polietilen visoke gustoće sastoji od najviše 10% težinskog udjela polipropilena i najviše 5% težinskog udjela crnih komponenata, u odnosu na ukupnu težinu spomenutog recikliranog polietilena visoke gustoće, i naznačeno time da se spomenuti reciklirani polietilen visoke gustoće sastoji od najmanje 50 ppm limonena (1- metil-4-(1-metiletenil)-cikloheksen, CAS br.
a second configuration, wherein said loading elements are at a distance from the second central axis corresponding to a second radius which is greater than said first radius, so as to stretch the fabric strip and let it adhere to the loading elements themselves, for a length corresponding to the axial size of the loading elements, and so that the length of fabric strip protruding above from the loading elements gets back to the second central axis and is stretched as far as the first welt; and/or 
- druge konfiguracije, gdje su navedeni elementi za punjenje udaljeni od druge središnje osi koja odgovara drugom polumjeru, većem od navedenog prvog polumjera, radi rastezanja trake od tkanine i puštanja da prianja na same elemente za punjenje, u duljini koja odgovara aksijalnoj veličini elemenata za punjenje, te tako da se duljina trake od tkanine koja proviruje odozgo od elemenata za punjenje vrati do druge središnje osi i rastegne sve do prvog obruba; i
Figure 12 illustrates the effect of 42-O-(D-fructosylcarbonyl)rapamycin and rapamycin on survival rates in a rat heart transplant model. 
Slika 12 ilustrira učinak 42-O-(D-fruktozilkarbonil)rapamicina i rapamicina na stopu preživljenja u modelu transplantacije srca štakora.
The process of claim 13, wherein the media particles have a median particle size in a range of from 10 µm to 1000 µm, or from 50 µm to 500 µm. 
Postupak sukladno zahtjevu 13, naznačeno time, da čestice medija imaju partikule srednje veličine koja je u rasponu od 10mm do 1000mm, ili od 50 mm do 500 mm.
R3 is selected from the group consisting of: 
se bira iz skupine koju čine:
The filters are dried and appropriate scintillation fluid (Optiphase Supermix) is added. 
Filteri se suše i dodaje se odgovarajući scintilacijski fluid (Optiphase Supermix).
The isolated monoclonal antibody or antigen-binding fragment of claim 1, wherein: at least one of the three CDRs of the VH domain comprises the amino acid sequence of SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, optionally wherein the three CDRs of the VH domain comprise the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12; and/or 
Izolirano monoklonsko protutijelo ili njegov fragment koji veže antigen, prema patentnom zahtjevu 1, naznačeno time, da barem jedna od tri CDR-regije VH domene obuhvaća aminokiselinsku sekvencu od SEQ ID NO: 10, SEQ ID NO: 11 ili SEQ ID NO: 12, gdje prema potrebi tri CDR-regije od VH domene sadrže aminokiselinske sekvence od SEQ ID NO: 10, SEQ ID NO: 11 i SEQ ID NO: 12, i/ili barem jedna od tri CDR-regije VL domene obuhvaća aminokiselinsku sekvencu od SEQ ID NO: 13, SEQ ID NO: 14 ili SEQ ID NO: 15, gdje prema potrebi tri CDR-regije od VL domene sadrže aminokiselinske sekvence od SEQ ID NO: 13, SEQ ID NO: 14 i SEQ ID NO: 15.
The process of any of claims 1 to 6, wherein the second conversion step is conducted for a second conversion time is greater than the first conversion time and less than a value selected from the group consisting of 72 hours, 60 hours, and 50 hours. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što se drugi korak pretvorbe provodi u vremenu druge pretvorbe koje je manje od 72 sata.
Use according to claim 6, wherein the disorder or disease is characterized by an abnormal activity of aromatase. 
Uporaba spoja prema zahtjevu 10, naznačena time, da je poremećaj ili bolest karakteriziran(a) s nenormalnim djelovanjem sinteze aldosterona,
The reaction flask was rinsed into the separatory funnel with 5%NaHCO3 (25mL) and, thereafter, the reaction mixture was shaken and the layers were separated. 
Tikvica za reakciju je bila isprana u lijevak za odjeljivanje s 5% NaHCO; (25 mL) i nakon toga reakcijska smjesa je bila protresena i slojevi su bili odvojeni.
core decoding means adapted for decoding the encoded bit stream separated by the bit stream separating means to obtain a low frequency component; frequency transform adapted for transforming the low frequency component obtained by the core decoding means into a frequency domain; high frequency generating means adapted for generating a high frequency component by copying the low frequency component transformed into the frequency domain by the frequency transform means from a low frequency band to a high frequency band; 
osnovnog dekodera za dekodiranje kodirane struje bitove koju izdvaja separator struje bitova kako bi se dobilo niskofrekventnu komponentu; pretvarača frekvencije za pretvorbu niskofrekventne komponente dobivene iz osnovnog dekodera u frekventno područje; visokofrekventnog generatora za generiranje visokofrekventne komponente kopiranjem niskofrekventne komponente koju pretvarač frekvencije pretvara u frekventno područje iz niskofrekventnog pojasa u visokofrekventni pojas;
is as defined in claim 1 and X is chloro which is then converted into iodo prior to coupling with compounds of formulae III and IV wherein Z, R1 and R8 are as defined in claim 1; and M is B or a metal. 
definiran u patentnom zahtjevu 1 i X je klor koji je zatim konvertiran u jod prije vezivanja sa spojevima koja su označena formulama III i IV. [image] pri čemu su Z, R1 i R8 definirani kao što je u patentnom zahtjevu 1; i M je B ili metal.
Metabolites of the Compounds of the Invention 
Broj objave europskog patenta:
A compound according to any one of claims 1 to 11 for use in the treatment of a pathological condition or disease susceptible to amelioration by antagonism of the adenosine A2a receptor. 
Spoj prema bilo kojem od zahtjeva 1 do 11 za primjenu u terapiji patološkog stanja ili bolesti podložnih poboljšanju radi antagonističkog djelovanja na adenozin A, receptor.
The composition of claim 7, for the use of claim 7, wherein said recipient is treated with FH upon receipt of said allograft until said allograft functions normally. 
Pripravak u skladu s patentnim zahtjevom 7, namijenjen upotrebi u skladu s patentnim zahtjevom 7, naznačen time što se navedenog primatelja obrađuje s FH prilikom primitka navedenog alogenog presatka dok navedeni alogeni presadak ne profunkcionira normalno.
In yet another particular embodiment, the at least one digital information items corresponds to the sign of a residual data item. Correlatively, the invention relates also to a device for decoding a data signal representative of at least one image split into partitions which has been previously encoded, comprising means for obtaining, by the entropy decoding of data items of the signal, digital information items associated with residual data items relating to at least one previously encoded partition. 
Uređaj (DO) za dekodiranje signala podataka koji predstavlja barem jednu sliku podijeljene u particije koja je bila prethodno kodirana, koji sadrži sredstva (DE_DO) za dobivanje, pomoću entropijskog dekodiranja stavki podataka za navedeni signal, digitalnih informacija povezanih sa preostalim stavkama podataka koje se odnose na barem jednu prethodno kodiranu particiju, te je skup preostalih stavki podataka postavljen u blok preostalih stavki podataka, te je navedeni uređaj za dekodiranje naznačen time da sadrži sredstva za obradu (MTR_DO) koja su sposobna za:
said water-miscible oil-based solvent comprises macrogolglycerol ricinoleate (Ph Eur); and/or 
sredstvo za poboljšanje okusa topivih u vodi; i / ili
at least one and at most two Y1, Y2, Y3, and Y4 groups represent a nitrogen atom, 
: najmanje jedan a najviše dvije od skupina Yi, Y2, Y3i Y4 predstavljaju dušikov atom, te
adjusting the pH of the mixture to be between 3.5 and 5.5 by adding a solution comprising a second dissolved acid to the mixture; and 
podešavanje pH smjese dodavanjem u smjesu otopine koja sadrži drugu otopljenu kiselinu; i
Optionally triggering the formation of a crystalline phase, and/or optionally improving the crystallinity of the crystalline phase, 
izbornog poticanja stvaranja kristalne faze, i/ili izbornog poboljšavanja kristalnosti kristalne faze,
introducing a saturated solution of at least one solute in a solvent to the ultrasonic flow cell chamber at a second flow rate, wherein the flow rate ratio of the non-solvent: the saturated solution is at least 20:1; 
Postupak u skladu s patentnim zahtjevom 2, pri čemu je udio protoka drugog tekućeg mlaza: prvi tekući mlaz najmanje 20:1 do 600:1.
Such agonists appear to function by binding to the GnRH receptor in the pituitary gonadotropins, thereby inducing the synthesis and release of gonadotropins. 
Takvi agonisti očigledno djeluju vezanjem na receptor GnRH u hipofizi za gonadotropine, inducirajući sintezu i otpuštanje gonadotropina.
A kit comprising a container containing the composition of item 17, preferably further comprising an anti-diarrheal agent. 
Kit naznačen time da sadrži spremnik koji sadrži pripravak prema zahtjevu 15, te poželjno dodatno sadrži sredstvo protiv proljeva.
The composition for use according to claim 7, wherein the subject exhibits one or more of: (a) a reduction in triglyceride level of at least about 30% as compared to baseline; (b) no increase in non-HDL-C levels as compared to baseline; (c) no decrease in HDL-C levels compared to baseline; and/or (d) a less than 30% increase in LDL-C levels as compared to baseline. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 7, naznačen time što subjekt pokazuje jedno ili više od sljedećeg: (a) snižavanje razina triglicerida od najmanje otprilike 30% u usporedbi s osnovnim vrijednostima; (b) nulto povišavanje razina ne-HDL-C u usporedbi s osnovnim vrijednostima; (c) nulto snižavanje razina HDL-C u usporedbi s osnovnim vrijednostima; i/ili (d) povišavanje razina LDL-C manje od 30% u usporedbi s osnovnim vrijednostima.
The injectable flowable composition for the use of claim 12 or claim 13, wherein the dosage achieves a therapeutically effective level of the buprenorphine within one day after administration of the implant; and wherein the therapeutically effective dosage of the buprenorphine is delivered for at least 15 days after administration of the implant, or for at least 30 days after administration of the implant, or for at least 45 days after administration of the implant, or for at least 60 days after administration of the implant. 
Tekući pripravak sukladno bilo kojem od zahtjeva 18 do 20, pri čemu doza postiže terapeutski učinkovitu razinu buprenorfina unutar jednog dana nakon davanja implantata; i pri čemu se terapeutski učinkovita doza buprenorfina isporučuje tijekom barem 15 dana nakon davanja implantata, ili tijekom barem 30 dana poslije davanja implantata, ili tijekom najmanje 45 dana nakon davanja implantata, ili barem za najmanje 60 dana nakon davanja implantata.
A packaging according to any of claims 1-4, wherein the first and second sides comprise indentations along a perimeter for receiving corresponding protrusions provided on said first and second outer parts so as to provide the attachment between said sides and said outer parts. 
Pakiranje u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačeno time, što prve i druge strane sadržavaju nazubljenja duž oboda radi prihvaćanja odgovarajućih izbočenja koja se nalaze na navedenim prvim i drugim vanjskim dijelovima, tako da osiguraju pričvršćenje između navedenih strana i navedenih vanjskih dijelova.
The isolated fusion protein for the use of any one of claims 1 to 11, wherein: the immunoglobulin Fc polypeptide is modified to enhance FcRn binding; the immunoglobulin Fc polypeptide comprises at least one of the following mutations: Met252Tyr, Ser254Thr, Thr256Glu, Met428Leu or Asn434Ser. 
Izolirani fuzijski protein za uporabu prema bilo kojem od patentnih zahtjeva 1 do 11, gdje: a. imunoglobulinski Fc polipeptid je modificiran tako da poboljšava vezivanje FcRn; b. imunoglobulinski Fc polipeptid sadrži najmanje jednu od sljedećih mutacija: Met252Tyr, Ser254Thr, Thr256Glu, Met428Leu ili Asn434Ser.
The compounds of formula (I) in the formulation may have different counter ions. 
PATENTNI ZAHTJEVI 1. - Oralna farmaceutska formulacija koja sadrži spoj formule (I): noO2
The use according to claim 6, wherein the renin inhibitor is a δ-amino-Y-hydroxy-w-aryl-alkanoic acid amide derivative, or a pharmaceutically acceptable salt thereof. 
Uporaba u skladu sa zahtjevom 6, naznačena time, da inhibitor renina je derivat amida δ-amino-Y-hidroksi-w-aril-alkanoične kiseline, ili je njegova farmaceutski prihvatljiva sol.
The method of claim 2, wherein the step is repeated until the codon pair bias is reduced by a desired amount. 
korak se ponavlja sve dok se pristranost para kodona ne smanji za željenu količinu, ili
The active compounds in the combination, i.e. the M3 antagonist of the invention, the PDE4 inhibitor and any other optional active compounds may be administered by any suitable route, depending on the nature of the disorder to be treated, e.g. orally (as syrups, tablets, capsules, lozenges, controlled-release preparations, fast-dissolving preparations, lozenges, etc); topically (as creams, ointments, lotions, nasal sprays or aerosols, etc); by injection (subcutaneous, intradermic, intramuscular, intravenous, etc.) or by inhalation (as a dry powder, a solution, a dispersion, etc). 
Djelatni spojevi u kombinacijama, tj. M3 antagonist sukladno predmetnom izumu, kortikosteroid i svi drugi izborni djelatni spojevi mogu se davati bilo kojom prikladnom rutom, ovisno o prirodi bolesti koja se liječi, npr. peroralno (u obliku sirupa, tableta, kapsula, pastila, pripravaka s nadziranim otpuštanjem, pripravaka s brzim otapanjem, pastila itd.); lokalno (u obliku krema, pomada, losiona, nazalnih sprejeva ili aerosola, itd.); uštrcavanjem (subkutano, intradermalno, intramuskularno, intravenski, itd.) ili inhalacijom (u obliku suhog praška, otopine, disperzije, itd.).
The pharmaceutical composition according to claim 9, further comprising one or more pharmaceutically acceptable excipients. 
Farmaceutski sastav prema zahtjevu 8, naznačen time, da nadalje sadrži jedno ili više farmaceutski prihvatljivih pomoćnih sredstava.
reacting a modified cytotoxic compound with a bifunctional crosslinking agent to form a second modified cytotoxic compound, wherein the modified cytotoxic compound is represented by the following formula: or a pharmaceutically acceptable salt thereof; the bifunctional crosslinking agent is N -succinimidyl-4-(2-pyridyldithio)2-sulfo butanoate (sulfo-SPDB); and the second modified cytotoxic compound is represented by the following formula: or a pharmaceutically acceptable salt thereof; and, 
Postupak pripreme konjugata koji sadrži agens za vezanje stanice (CBA) koji je konjugiran na citotoksični spoj s vezujućom skupinom, postupak sadrži reagiranje CBA s citotoksičnim spojem koje sadrži imin, imin reaktivnim reagensom i bifunkcionalnim umrežavajućim agensom koji sadrži vezujuću skupinu kako bi se formirao konjugat, naznačen time što je citotoksični spoj koji sadrži imin predstavljen bilo kojom od sljedećih formula ili njihovom farmaceutski prihvatljivom soli: pri čemu:
In further embodiments, a1-adrenergic receptor agonist is preferably oxymetazoline, naphazoline, tetrahydrozoline, and phenylephrine hydrochloride. 
Agonist za uporabu u skladu sa zahtjevom 3, naznačen time što je selektivni agonist alfa 1 adrenergijskog receptora oksimetazolin hidroklorid.
The groove structures are filled either completely or only partially such that at least openings of the groove structures being exposed to the exterior or mechanical machining are blocked by the filling medium so that the groove structures can not be contaminated by swarf, cooling lubricant or the like during mechanical machining of the composite structure. 
Brazdaste strukture se pune potpuno ili samo djelomično tako, da su barem otvori brazdastih struktura izloženi prema van, ili se mehaničku strojnu obradu zaustavlja s punilom tako da se kompozitne strukture brazdaste strukture tijekom mehaničke strojne obrade ne mogu onečistiti sa strugotinama, rashladnim sredstvom za podmazivanje ili sličnim.
A compound according to claim 1 wherein the compound is a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. 
Spoj sukladno zahtjevu 1, naznačen time, da je spoj N-oksid te vrste, farmaceutski prihvatljiva sol ili solvat te vrste.
The method of claim 1, wherein the compound is represented by the following formula: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što spoj ima formulu:
is receiving interferon therapy; is receiving anti-viral therapy; and 
(d) prima interferonsku terapiju; (e) prima antivirusnu terapiju; i
Thus, an excipient such as lactose, manitol or glucose is generally employed. 
Stoga se općenito koriste ekscipijensi poput laktoze, manitola ili glukoze.
2-[4-(4-Pyridin-4yl-isoxazol-5-yl)-phenoxymethyl]-quinoline; and pharmecutical acceptable salts thereof. A process for forming the compound of Formula I in claim 1, comprising a step of reacting a compound of formula IV 
2-43-fMuoro-4-[4-piridin-4-il-1-(2,2,2-trifluoroetil)-177-pirazol-3-ilJfenoksimetiljhinolin; i njihove farmaceutski prihvatljive soli. 15. Postupak za dobivanje spoja formule I, definiranog u Zahtjevu 1, koji se sastoji od koraka reagiranja spoja formule
The method of claim 1, wherein said disease is Chagas disease, and said second agent is selected from benznidazole, nifurtimox and Amphotericin. A combination comprising a therapeutically effective amount of a compound of Formula (A), or a pharmaceutically acceptable salt, or stereoisomer thereof, and a second therapeutic agent; 
Spoj ili njegova farmaceutski prihvatljiva sol ili pripravak za uporabu prema zahtjevu 17, naznačen time, da se nalazi u kombinaciji s drugim sredstvom, pri čemu je bolest Chagasova bolest 1 drugo sredstvo je odabrano od benznidazola, nifurtimoksa i amfotericina.
Example 7 Dissolution of Lozenges 
Primjer 7-Otapanje tableta
said precipitated glycine is filtered and the resulting filtrate is concentrated until a precipitate of Metformin glycinate is produced, 
istaloženi glicin se filtrira i dobiveni filtrat se koncentrira da se dobije talog metformin glicinata,
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) cyprodinil. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5ilamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
Suitable GnRH antagonists are capable of inhibiting the specific binding of GnRH to its receptor and antagonizing activities associated with GnRH. 
Pogodni antagonisti GnRH mogu inhibirati specifično vezanje GnRH na njegov receptor i antagonizirati aktivnosti povezane s GnRH.
The resulting yellow solution was washed with ether (2 x 50 ml) and basified by the slow addition of solid sodium carbonate (ca. 13 g). 
Rezultirajuća žuta otopina se ispere eterom (2 x 50 ml) 1 zalužni polaganim dodavanjem krutog natrij karbonata (oko 13 g).
The fuel element was inserted 2 mm into a 20 mm long foil lined tube of the type described in Example 1. 
Gorivi element je umetnut 2 mm u cijev koja je obložena sa folijom dugu 20 mm tipa koji je opisan u Primjeru 1.